Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Rezultati zdravljenja bolnikov s karcinomom požiralnika[,] zdravljenih na Onkološkem inštitutu Ljubljana v letih 2006-2010
Authors:ID Anderluh, Franc (Author)
ID Perpar, Ana (Author)
ID Velenik, Vaneja (Author)
ID Oblak, Irena (Author)
Files:.pdf PDF - Presentation file, download (1,29 MB)
MD5: DC85B43768A747666D520EA81F5FD5B8
PID: 20.500.12556/dirros/d7cff089-62b3-4803-aab6-1d596e9b232e
 
Language:Slovenian
Typology:1.02 - Review Article
Organization:Logo OI - Institute of Oncology
Abstract:Karcinom požiralnika je relativno redka bolezen s slabo prognozo. Namen naše retrospektivne raziskave je bil oceniti različne načine in rezultate zdravljenja bolnikov z rakom požiralnika, ki so bili v obdobju od leta 2006 do 2010 obravnavani na Onkološkem inštitutu v Ljubljani (OIL). V raziskavo je bilo vključenih 151 bolnikov, od katerih jih je bilo 74 zdravljenih paliativno in 75 radikalno. Pri dveh bolnikih je bilo načrtovano radikalno zdravljenje, vendar sta zaradi zapletov s hitrim poslabšenjem splošnega stanja prejela le podporno zdravljenje. Petletno celokupno preživetje (CP) je za vse bolnike znašalo 9.5%, za zdravljene paliativno 0% in zdravljene radikalno 18.7%. Ustrezne vrednosti za petletno preživetje brez progresa bolezni (PBP) so bile za vse bolnike 22.4% in za zdravljene radikalno 29.6%. V skupini radikalno zdravljenih bolnikov je bila opravljena tudi primerjava preživetij med skupino 50 bolnikov, ki so bili zdravljeni samo z obsevanjem z ali brez sočasne kemoterapije in skupino 25 bolnikov, ki so bili pred ali po radio- in/ali kemoterapiji tudi operirani. Med podskupinama statistično pomembne razlike v CP (p=0.42) in v PBP (p=0.31) ni bilo. Rezultati zdravljenja teh bolnikov so v Sloveniji slabi, vendar ne odstopajo bistveno od prav tako slabih rezultatov iz raziskave EUROCARE-5. Odgovor na vprašanje ali bomo pri zdravljenju raka požiralnika z dosledno uporabo trimodalnega zdravljenja (pri izbranih bolnikih) in morebitno uporabo novih kemoterapevtskih shem dosegli kakršenkoli napredek, bodo lahko dale samo dobro načrtovane in izpeljane prospektivne raziskave .
Keywords:rak požiralnika, bolniki, zdravljenje, preživetje
Publication status:Published
Publication version:Version of Record
Year of publishing:2014
Number of pages:str. 84-88, 118
Numbering:Letn. 18, št. 2
PID:20.500.12556/DiRROS-8637 New window
UDC:616.21
ISSN on article:1408-1741
URN:URN:NBN:SI:doc-369BGF3L
COBISS.SI-ID:1962875 New window
Copyright:by Authors
Publication date in DiRROS:31.08.2018
Views:3861
Downloads:1085
Metadata:XML DC-XML DC-RDF
:
ANDERLUH, Franc, PERPAR, Ana, VELENIK, Vaneja and OBLAK, Irena, 2014, Rezultati zdravljenja bolnikov s karcinomom požiralnika[,] zdravljenih na Onkološkem inštitutu Ljubljana v letih 2006-2010. Onkologija [online]. 2014. Vol. 18, no. 2, p. 84–88, 118. [Accessed 26 March 2025]. Retrieved from: https://dirros.openscience.si/IzpisGradiva.php?lang=eng&id=8637
Copy citation
  
Share:Bookmark and Share



Similar works from other repositories:

No similar works found

Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:Treatment results in patients with esophageal carcinoma treated at the Institute of oncology in Ljubljana from 2006–2010
Abstract:Esophageal carcinoma is a relatively rare disease with bad prognosis. The purpose of our retrospective study was to evaluate the methods and results of treatment of patients with esophageal cancer, who were treated at the Institute of Oncology in Ljubljana (OIL) from 2006 to 2010. The study included 151 patients, of whom 74 received palliative treatment and 75 radical treatment. In two patients radical treatment had been planned, but because of rapidly progressing complications and deteriorating general condition they only received supporting treatment. The five-year overall survival (OS) rate for all patients amounted to 9.5%, of those receiving palliative treatment 0% and those receiving radical treatment 18.7%. The corresponding values for five-year progression-free survival (PFS) rate were for all patients 22.4% and for radically treated patients 29.6%. In radically treated patients we also performed a survival comparison study between the group of 50 patients, who were treated only with radiation with or without simultaneous chemotherapy and the group of 25 patients, who had also been operated either prior or post radio and/ or chemotherapy. There were no significant differences among the subgroups in OS (p=0.42) or PFS (p=0.31). The results of treatment of these patients in Slovenia are poor, but do not substantially differ from the likely poor results from the EUROCARE-5 study. Whether consistent trimodality therapy in treating esophageal cancer (in selected patients) and potential use of new chemotherapeutic schemes can achieve any kind of progress, is a question, which only carefully planned and implemented prospective studies can answer.


Archive

niGradiv

Back